CN104116796A - Medicinal composition for treating hyperplasia of mammary glands - Google Patents
Medicinal composition for treating hyperplasia of mammary glands Download PDFInfo
- Publication number
- CN104116796A CN104116796A CN201410394695.6A CN201410394695A CN104116796A CN 104116796 A CN104116796 A CN 104116796A CN 201410394695 A CN201410394695 A CN 201410394695A CN 104116796 A CN104116796 A CN 104116796A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- herba
- treatment
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a medicinal composition for treating hyperplasia of mammary glands. The medicinal composition comprises liquorice, radix paeoniae alba, angelica root, erigeron annuus, folium ilicis purpurea, swamp mahogany leaf, rhizoma curculiginis and other medicinal materials. The medicinal composition for treating hyperplasia of mammary glands has the advantages of good curative effect, high cure rate, low cost, wide drug source, no toxic or side effect, stable curative effect, relapse prevention and the like.
Description
Technical field
The present invention relates to Gynecology, relate in particular to a kind of pharmaceutical composition for the treatment of cyclomastopathy.
Background technology
Cyclomastopathy is clinical modal cystic hyperplasia of breast, and its sickness rate accounts for the women of child-bearing age's 30%-50%, and 3/4 and morbidity of mastopathy is still the trend of rising.Research both at home and abroad shows, cyclomastopathy and breast carcinoma have close relationship, there is breast cancer risk than the high 1.4-1.5 of healthy women doubly in it, modern medicine thinks that cyclomastopathy is due to endocrine disturbance, estrogen increases or estrogen and progestogen is out of proportion and mammary gland tissue in due to estrogen receptor increases.Be multiple disease clinically at present, therefore need constantly to find new effective medicine.
Summary of the invention
The object of this invention is to provide a kind of pharmaceutical composition for the treatment of cyclomastopathy.
In order to realize object of the present invention, the invention provides a kind of pharmaceutical composition for the treatment of cyclomastopathy, the crude drug that it comprises following weight portion: Radix Glycyrrhizae 1-20 part, Radix Paeoniae Alba 10-30 part and Radix Angelicae Dahuricae 1-10 part.
Preferably, the crude drug that the pharmaceutical composition for the treatment of cyclomastopathy of the present invention comprises following weight portion: 8 parts of 10 parts, Radix Glycyrrhizae, 15 parts of the Radix Paeoniae Albas and the Radixs Angelicae Dahuricae.
More preferably, the pharmaceutical composition for the treatment of cyclomastopathy of the present invention also comprises the crude drug of following weight portion: Herba Erigerontis Annui 10-20 part, Ilex purpurea Hassk.[I.chinensis Sims 10-30 part, Folium Eucalypti Robustae 1-20 part, Rhizoma Curculiginis 1-10 part, Herba Ixeritis chinensis 1-5 part, Herba Liparidis nervosae 10-30 part, Radix Pulsatillae 1-20 part, Herba Fimbristylis dichotomae 10-30 part, when medicine 1-10 part, sow grass 1-10 part, tetramerous jasminorange leaf 1-10 part, Semen Myristicae 1-10 part, GUANGXIANG rattan 10-30 part, Radix Polygalae 1-10 part, little Rubus pectinellus 10-30 part and Lindera angustifolia Cheng 10-20 part.
Most preferably, the pharmaceutical composition for the treatment of cyclomastopathy of the present invention also comprises the crude drug of following weight portion: 15 parts of Herba Erigerontis Annuis, 20 parts of Ilex purpurea Hassk.[I.chinensis Sims, 10 parts of Folium Eucalypti Robustaes, 5 parts of Rhizoma Curculiginises, 3 parts of Herba Ixeritis chinensiss, 15 parts of Herba Liparidis nervosaes, 10 parts of the Radix Pulsatillaes, 20 parts of Herba Fimbristylis dichotomae, when 12 parts of 9 parts of medicines, 8 parts of sow grass, 6 parts of tetramerous jasminorange leafs, 5 parts of Semen Myristicaes, 15 parts, GUANGXIANG rattan, 6 parts of Radix Polygalaes, 20 parts of little Rubus pectinellus and Lindera angustifolia Chengs.
Preferably, described pharmaceutical composition can be tablet, dispersible tablet, disintegrating tablet, instant, enteric coatel tablets, ointment or decoction.
Generally acknowledged that at present " organic conception ", " determination for the treatment of based on pathogenesis obtained through differentiation of symptoms and signs ", " compound recipe use ", " compound compatibility medication is as used military forces " are the most scientific the most several large advantages of the traditional Chinese medical science, wherein " compound compatibility medication is as used military forces " is the original theory of Chinese medicine of very science.Each medicine tight compatibility all linked with one another as arrayed troops for battle in traditional Chinese medical science prescription is its effective means that is better than Western medicine formula.Tcm prescription theory is thought, each prescription, not only need to select the appropriate compatibility of suitable medicament according to etiology and pathogenesis, also should meet the basic structure of prescription simultaneously, the i.e. prescription compatibility theory of " monarch, minister, help, make ", the prescription compatibility of so-called " monarch, minister, help, make " is exactly that it is based upon the scientific matching on the comprehensive judgement basis of disease pathogenesis.In medical square tube cross too many levels, many target spots and integrate the biological mechanism regulating, can obtain than Western medicine more lastingly, therapeutic effect that more green natural has no side effect, and this curative effect is to be based upon on the accurate instruction of the original theory of above-mentioned traditional Chinese medical science tradition, the present invention is just following this principle.
For compositions of the present invention, according to the prescription compatibility theory of " monarch, minister, help, make ", Herba Fimbristylis dichotomae and little Rubus pectinellus are monarch drug; Herba Erigerontis Annui, the Radix Paeoniae Alba, Ilex purpurea Hassk.[I.chinensis Sims, Herba Liparidis nervosae, the Radix Pulsatillae, GUANGXIANG rattan are ministerial drug; The Radix Angelicae Dahuricae, Folium Eucalypti Robustae, Rhizoma Curculiginis, Herba Ixeritis chinensis, when medicine, sow grass, tetramerous jasminorange leaf, Semen Myristicae, Radix Polygalae, Lindera angustifolia Cheng be adjuvant drug; Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription, for making medicine.The pharmaceutical composition for the treatment of cyclomastopathy of the present invention has good effect, and cure rate is high, and cost is low, and medicine source is wide, without any side effects, and stable curative effect is difficult for the advantages such as recurrence.
Detailed description of the invention
Further illustrate the present invention below by embodiment.It should be understood that embodiments of the invention are for the present invention instead of limitation of the present invention are described.The simple modifications that essence according to the present invention is carried out the present invention all belongs to the scope of protection of present invention.Except as otherwise noted, the percent otherwise in the present invention is percetage by weight.
Embodiment ointment of the present invention
Take 10 grams, Radix Glycyrrhizae, 15 grams of the Radix Paeoniae Albas, 8 grams of the Radixs Angelicae Dahuricae, 15 grams of Herba Erigerontis Annuis, 20 grams of Ilex purpurea Hassk.[I.chinensis Sims, 10 grams of Folium Eucalypti Robustaes, 5 grams of Rhizoma Curculiginises, 3 grams of Herba Ixeritis chinensiss, 15 grams of Herba Liparidis nervosaes, 10 grams of the Radix Pulsatillaes, 20 grams of Herba Fimbristylis dichotomae, when 12 grams of 9 grams of medicines, 8 grams of sow grass, 6 grams of tetramerous jasminorange leafs, 5 grams of Semen Myristicaes, 15 grams, GUANGXIANG rattan, 6 grams of Radix Polygalaes, 20 grams of little Rubus pectinellus and Lindera angustifolia Chengs, pulverize, cross 100 mesh sieves, add 200 grams of lanolines, stir, obtain ointment of the present invention.
Experimental example
Physical data
Be collected in year March in March, 2013 to 2014 to medical female patient 30 examples of my institute, minimum 18 years old of age, maximum 65 years old, average 36 years old; The course of disease is the shortest 30 days, the longest 1 year, one-sided ill 15 examples of breast, ill 15 examples of bilateral.
Inclusion criteria
(1) meet Shanghai Health Bureau in 2003 compile " Shanghai City traditional Chinese medical science disease conventional treatment " (Shanghai Health Bureau. Shanghai City traditional Chinese medical science disease conventional treatment [M] .2 version. Shanghai: publishing house of Shanghai Univ. of Traditional Chinese Medicine, the diagnosis basis of nodules of the breast 2003:159), and through the inspection of mammary gland Color B-Type Ultrasonic be diagnosed as cyclomastopathy and except other pathological changes.(2) before this time treatment, stopped using related drugs treatment to reach more than 2 weeks.(3) development of breast that except, other reasons causes abnormal (as trimester of pregnancy, age of sucking, medicine cause, pituitary tumor).
Treat with the ointment of preparing in embodiment, every day twice, on each ill breast, evenly apply 30 grams at every turn, treat continuously 10 days.
Observation index
(1) observe 6 of estrogen: before and after all cases treatment, all carry out blood test and measure 6 hormonal readinesses such as serum glycol luteal phase (E2), progesterone (P), testosterone (T), follicule-stimulating hormone (FSH) (FSH), lutropin (LH), lactotropin (PRL), gonadal hormone situation of change before and after understanding treatment.(2) clinical observation: the main treatment front and back clinical symptoms sign situation of change of observing, is mainly mastalgia, lump in breast situation of change.
Criterion of therapeutical effect
Efficacy assessment standard
By Shanghai Health Bureau in 2003 compile " Shanghai City traditional Chinese medical science disease conventional treatment " (Shanghai Health Bureau. Shanghai City traditional Chinese medical science disease conventional treatment [M] .2 version. Shanghai: publishing house of Shanghai Univ. of Traditional Chinese Medicine, 2003:159) formulate criterion of therapeutical effect:
Cure: mastalgia and lump disappear; Take a turn for the better: lump in breast dwindles, pain obviously alleviates even disappearance; Invalid: lump in breast and pain even increase the weight of without improving.
Result
Through treatment, find, in 30 routine patients, to cure 26 examples, 4 examples take a turn for the better.
Before and after treatment, clinical symptoms and sign improvement see the following form
After visible treatment, patient's symptom and sign all obviously improves (P<0.01).
The serum indices luteal phase variation for the treatment of front and back relatively sees the following form
Note: relatively front with treatment, * P < 0 05.
Claims (5)
1. a pharmaceutical composition for the treatment of cyclomastopathy, is characterized in that, the crude drug that it comprises following weight portion: Radix Glycyrrhizae 1-20 part, Radix Paeoniae Alba 10-30 part and Radix Angelicae Dahuricae 1-10 part.
2. the pharmaceutical composition for the treatment of cyclomastopathy according to claim 1, is characterized in that, the crude drug that it comprises following weight portion: 8 parts of 10 parts, Radix Glycyrrhizae, 15 parts of the Radix Paeoniae Albas and the Radixs Angelicae Dahuricae.
3. the pharmaceutical composition for the treatment of cyclomastopathy according to claim 1 and 2, it is characterized in that, it also comprises the crude drug of following weight portion: Herba Erigerontis Annui 10-20 part, Ilex purpurea Hassk.[I.chinensis Sims 10-30 part, Folium Eucalypti Robustae 1-20 part, Rhizoma Curculiginis 1-10 part, Herba Ixeritis chinensis 1-5 part, Herba Liparidis nervosae 10-30 part, Radix Pulsatillae 1-20 part, Herba Fimbristylis dichotomae 10-30 part, when medicine 1-10 part, sow grass 1-10 part, tetramerous jasminorange leaf 1-10 part, Semen Myristicae 1-10 part, GUANGXIANG rattan 10-30 part, Radix Polygalae 1-10 part, little Rubus pectinellus 10-30 part and Lindera angustifolia Cheng 10-20 part.
4. the pharmaceutical composition for the treatment of cyclomastopathy according to claim 3, it is characterized in that, it also comprises the crude drug of following weight portion: 15 parts of Herba Erigerontis Annuis, 20 parts of Ilex purpurea Hassk.[I.chinensis Sims, 10 parts of Folium Eucalypti Robustaes, 5 parts of Rhizoma Curculiginises, 3 parts of Herba Ixeritis chinensiss, 15 parts of Herba Liparidis nervosaes, 10 parts of the Radix Pulsatillaes, 20 parts of Herba Fimbristylis dichotomae, when 12 parts of 9 parts of medicines, 8 parts of sow grass, 6 parts of tetramerous jasminorange leafs, 5 parts of Semen Myristicaes, 15 parts, GUANGXIANG rattan, 6 parts of Radix Polygalaes, 20 parts of little Rubus pectinellus and Lindera angustifolia Chengs.
5. according to the pharmaceutical composition of the treatment cyclomastopathy described in any one in claim 1 to 4, it is characterized in that, described pharmaceutical composition can be tablet, dispersible tablet, disintegrating tablet, instant, enteric coatel tablets, ointment or decoction.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410394695.6A CN104116796B (en) | 2014-08-12 | 2014-08-12 | A kind of pharmaceutical composition for the treatment of cyclomastopathy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410394695.6A CN104116796B (en) | 2014-08-12 | 2014-08-12 | A kind of pharmaceutical composition for the treatment of cyclomastopathy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104116796A true CN104116796A (en) | 2014-10-29 |
| CN104116796B CN104116796B (en) | 2016-03-09 |
Family
ID=51762576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410394695.6A Expired - Fee Related CN104116796B (en) | 2014-08-12 | 2014-08-12 | A kind of pharmaceutical composition for the treatment of cyclomastopathy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104116796B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105558691A (en) * | 2015-12-19 | 2016-05-11 | 韦盛盟 | Drink for preventing and treating breast nodules and preparation method thereof |
| CN105559061A (en) * | 2015-12-19 | 2016-05-11 | 韦盛盟 | Instant powder for treating breast nodules and preparation method thereof |
| CN111700962A (en) * | 2020-08-09 | 2020-09-25 | 仲崇允 | External traditional Chinese medicine preparation for treating mastitis |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1569187A (en) * | 2004-04-27 | 2005-01-26 | 秦学彬 | Pure Chinese medicine for treating infecundity, dysgenesia and mastopathia |
| CN101564521A (en) * | 2009-05-20 | 2009-10-28 | 石振刚 | External plaster for treating hyperplasia of mammary glands |
| CN102091296A (en) * | 2011-01-24 | 2011-06-15 | 郭智义 | Medicament for treating breast hyperplasia |
-
2014
- 2014-08-12 CN CN201410394695.6A patent/CN104116796B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1569187A (en) * | 2004-04-27 | 2005-01-26 | 秦学彬 | Pure Chinese medicine for treating infecundity, dysgenesia and mastopathia |
| CN101564521A (en) * | 2009-05-20 | 2009-10-28 | 石振刚 | External plaster for treating hyperplasia of mammary glands |
| CN102091296A (en) * | 2011-01-24 | 2011-06-15 | 郭智义 | Medicament for treating breast hyperplasia |
Non-Patent Citations (2)
| Title |
|---|
| 李政: "乳腺增生病辨治体会", 《江苏中医药》, 31 December 2012 (2012-12-31) * |
| 胡德祥: "中医药治疗乳腺增生病概况", 《河北中医》, no. 04, 28 April 2008 (2008-04-28) * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105558691A (en) * | 2015-12-19 | 2016-05-11 | 韦盛盟 | Drink for preventing and treating breast nodules and preparation method thereof |
| CN105559061A (en) * | 2015-12-19 | 2016-05-11 | 韦盛盟 | Instant powder for treating breast nodules and preparation method thereof |
| CN111700962A (en) * | 2020-08-09 | 2020-09-25 | 仲崇允 | External traditional Chinese medicine preparation for treating mastitis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104116796B (en) | 2016-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105147811B (en) | A kind of external medicine composition and preparation method thereof for preventing and treating hand-foot syndrome | |
| CN101584797A (en) | Application of traditional Chinese medicine composition in preparing medicament for treating climacteric syndrome | |
| CN102120017B (en) | Chinese medicinal preparation for treating uterus myoma | |
| US11129863B2 (en) | Composition, preparation method thereof, and application thereof in the prevention and treatment of mammary gland disease | |
| CN106334060B (en) | Pharmaceutical composition for treating obesity type polycystic ovarian syndrome | |
| CN104116796B (en) | A kind of pharmaceutical composition for the treatment of cyclomastopathy | |
| CN103479887B (en) | Traditional Chinese medicine formula for treating climacteric dysfunctional uterine bleeding | |
| CN102755600B (en) | Traditional Chinese medicine compound for resisting breast cancer metastasis and reoccurrence, preparation method and uses | |
| CN102698014A (en) | Chinese medicinal composition for treating bone-related diseases and preparation method and application thereof | |
| CN102988887A (en) | Chinese medicament for treating ovarian cyst | |
| CN101991811B (en) | Traditional Chinese medicine composition for treating rheumatism arthralgia, cold headache, abdominal cavity pain and chilblain and preparation method thereof | |
| CN102784361B (en) | Traditional Chinese medicine composition for treating breast hyperplasia | |
| CN104491459A (en) | Traditional Chinese medicine composition for treating tumors | |
| CN101693084B (en) | Medical composition for treating epigastric pain yin deficiency syndrome and preparation method thereof | |
| CN103479737A (en) | Traditional Chinese medicine composition for treating senile cutaneous pruritus and application thereof | |
| CN100406026C (en) | Medicine for treating chronic gastritis and gastric carcinoma, and its prepn. method | |
| CN105982906A (en) | Application of 20(R)-ginsenoside Rg3 in preparing medicines or health products capable of alleviating or/and treating rheumatoid diseases and medicines | |
| CN103860786A (en) | Medicine for treating puerperal fever | |
| CN102600436A (en) | Traditional Chinese medicine compound preparation for treating gastric cancer and preparation method thereof | |
| CN102716424A (en) | Breast nodule treatment medicine composition and preparation process and application thereof | |
| CN105169106A (en) | Traditional Chinese medicinal preparation for treating hyperplasia of mammary glands | |
| CN105250952B (en) | A kind of Chinese medicine composition for treating uterus adenomyosis | |
| CN105456956A (en) | Traditional Chinese medicine for treating myoma of uterus | |
| CN105168868A (en) | Traditional Chinese medicine for treating thyroiditis and preparing method thereof | |
| CN106266500B (en) | A kind of Chinese medicine composition for treating the proliferation of mammary gland |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160309 Termination date: 20160812 |